Redmile Group, LLC 4
4 · FATE THERAPEUTICS INC · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
Fate Therapeutics (FATE) 10% Owner Redmile Receives Option Award
What Happened
- Redmile Group, LLC (a reported 10% owner) was granted a derivative stock option award for 87,900 shares of Fate Therapeutics (FATE) on June 12, 2026. The award shows a $0.00 acquisition price (i.e., a grant of options/rights rather than a cash purchase or sale).
Key Details
- Transaction date: 2026-06-12; Form 4 filed: 2026-06-15 (filed within the typical two-business-day window).
- Transaction type: A = Award/Grant of a derivative security (stock option) for 87,900 shares at $0.00.
- Vesting: The option vests in full on the earlier of (i) June 12, 2027 or (ii) the Issuer’s 2027 Annual Meeting, subject to Michael Lee’s continued board service (per footnote).
- Ownership after transaction: The filing does not state total shares/options held by Redmile after this grant.
- Reporting/beneficial ownership notes: Award was granted to Michael Lee as a nominee for Redmile; Mr. Lee assigned all economic/ voting rights to Redmile and disclaims beneficial ownership. The award may also be deemed beneficially owned by Jeremy Green (principal of Redmile); Redmile and Mr. Green disclaim ownership except to the extent of any pecuniary interest.
- Insider role: Michael Lee serves on the issuer’s board as Redmile’s representative (director by deputization).
Context
- This is an institutional director-related equity award (a grant of options), not an open-market buy or sale. Such awards compensate service and do not necessarily signal immediate buying or selling intent. The grant vests based on continued board service rather than immediate exercise; there is no cashless exercise or sale reported here.
Insider Transaction Report
Form 4
Redmile Group, LLC
Director10% Owner
Transactions
- Award
Stock Option (Right to Buy)
[F1][F2][F3][F4]2026-06-12+87,900→ 87,900 total(indirect: See Footnotes)Exercise: $2.06Exp: 2036-06-12→ Common Stock (87,900 underlying)
Footnotes (4)
- [F1]The stock option will vest in full and become exercisable upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date.
- [F2]The stock option award was granted to Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the board of directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this equity award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the equity award to Redmile. Mr. Lee disclaims beneficial ownership of the equity award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F3]The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the equity award except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F4]Mr. Lee, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.